GlaxoSmithKline Gets Positive Test Results For Incruse Ellipta

Tue, 20th Oct 2015 12:11

LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said it has received positive data on the efficacy and safety of its Incruse Ellipta treatment for patients with chronic obstructive pulmonary disease.

The results from the randomised, blinded 201316 study of the treatment showed a once-daily dose of Incruse Ellipta showed a statistically significant improvement in lung function against tiotropium, while study 201315 showed the treatment was not inferior to glycopyrronium.

Tiotropium and glycopyrronium are two existing treatment for COPD.

Shares in Glaxo were up 0.7% to 1,354.00 pence on Tuesday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Related Shares

More News

27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used...

24 May 2024 15:19

London close: Stocks mixed after disappointing retail sales data

(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted...

24 May 2024 08:55

LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April

(Alliance News) - Stock prices in London opened lower on Friday, with sentiment hurt across the globe.

24 May 2024 08:36

TOP NEWS: GSK celebrates Illinois jury verdict in Valadez case

(Alliance News) - GSK PLC on Friday welcomed the jury verdict in the Valadez case in Illinois state court, which found in GSK's favour in the first Za...

24 May 2024 07:52

LONDON BRIEFING: UK retail sales fall amid wet April; Co-Op Bank deal

(Alliance News) - Stocks are called to open lower on Friday, following New York lower, as hopes of interest rate cuts have come into question.